DHS 75.59(13)(g)3.3. The patient is not known to have engaged in criminal activity in the previous year. DHS 75.59(13)(h)1.a.a. For patient time in treatment starting day 31 through day 90, the patient shall be allowed no more than one take-home dose of medication per week. DHS 75.59(13)(h)1.b.b. For patient time in treatment starting day 91 through 180, the patient shall be allowed no more than 2 take-home doses of medication per week. DHS 75.59(13)(h)1.c.c. For patient time in treatment starting day 181 through day 270, the patient shall be allowed no more than 3 take-home doses of medication per week. DHS 75.59(13)(h)1.d.d. For patient time in treatment starting day 271 through day 365, the patient shall be allowed no more than 4 take-home doses of medication per week. DHS 75.59(13)(h)1.e.e. For patient time in treatment starting day 366 through day 730, the patient shall be allowed no more than 6 take-home doses of medication per week. DHS 75.59(13)(h)1.f.f. For patient time in treatment starting day 731 through completion of treatment, the patient shall be allowed no more than 13 take-home doses every 2 weeks. DHS 75.59(13)(h)2.2. Buprenorphine Oral Products shall be provided on a take-home basis as follows: DHS 75.59(13)(h)2.a.a. For patient time in treatment starting day 31 through day 60, the patient shall be allowed no more than 1 take-home dose of medication per week. DHS 75.59(13)(h)2.b.b. For patient time in treatment starting day 61 through day 90, the patient shall be allowed no more than 2 take-home doses of medication per week. DHS 75.59(13)(h)2.c.c. For patient time in treatment starting day 91 through day 120, the patient shall be allowed no more than 3 take-home doses of medication per week. DHS 75.59(13)(h)2.d.d. For patient time in treatment starting day 121 through day 240, the patient shall be allowed no more than 4 take-home doses of medication per week. DHS 75.59(13)(h)2.e.e. For patient time in treatment starting day 241 through day 365, the patient shall be allowed no more than 6 take-home doses of medication per week. DHS 75.59(13)(h)2.f.f. For patient time in treatment starting day 366 through completion of treatment, the patient shall be allowed no more than 13 take-home doses every 2 weeks. DHS 75.59(13)(i)(i) Denial or rescinding of approval. A service shall deny or rescind approval for take-home privileges for any of the following reasons: DHS 75.59(13)(i)3.3. The absence of laboratory evidence of FDA-approved narcotic treatment in test samples, including serum levels. DHS 75.59(13)(j)1.1. The service physician shall review the status of every patient provided with take-home medication at least every 90 days and more frequently if clinically indicated. DHS 75.59(13)(j)2.2. The service treatment team shall review the merits and detriments of continuing a patient’s take-home privilege and shall make appropriate recommendations to the service physician as part of the service physician’s 90-day review. DHS 75.59(13)(j)3.3. Service staff shall use biochemical monitoring to ensure that a patient with take-home privileges is not using illicit substances and is consuming the FDA-approved narcotic provided. DHS 75.59(13)(j)4.4. Service staff may not recommend denial or rescinding of a patient’s take-home privilege to punish the patient for an action not related to meeting requirements for take-home privileges. DHS 75.59(13)(k)(k) Reduction of take-home privileges or requirement of more frequent visits to the service.